Product name: Saxagliptin

CAS: 361442-04-8

Molecular formula: C18H25N3O2

Molecular weight: 315.414

Description: Saxagliptin (rINN), previously identified as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. In June 2008, it was announced that Onglyza would be the trade name under which saxagliptin will be marketed.

While used for type 2 diabetes the evidence does not show a change in hard end points such as the risk of heart attacks or strokes.